Background: Various endocrine signals oscillate over the 24-hour period and so
| INTRODUCTION
A significant component of endocrine signals exhibits a variable secretory pattern as hormones governed by the hypothalamic-pituitary axis (HPA) exhibit a 24-hours fluctuation pattern. 1 Furthermore, nutrient-sensitive hormones (insulin, adipokines, ghrelin) vary according to environmental parameters, such as light/dark exposure and feeding/fasting state, in time-of-day-dependent patterns. 2, 3 Biological rhythms are produced by conserved transcription and translation feedback loops of clock genes within the cells. The periodic expression of these clock genes establishes a 24-hour dynamic state of equilibrium for basic cell functions, such as cell metabolism and cell cycle. 4 To achieve a physiological and behavioural functional status according to the 24-hour environmental light/dark cycle, mammals rely on a central pacemaker known as the suprachiasmatic nucleus (SCN) for systemic synchronization. 4 SCN resides at the anterior hypothalamus and directly contacts optic chiasm for sensing the external photic input. [4] [5] [6] [7] The circadian clock is generated by a transcriptional autoregulatory feedback loop involving core clock genes of the endogenous circadian timing system that includes the suprachiasmatic nucleus (SNC) in the hypothalamus, as well as peripheral oscillators in different organs. [4] [5] [6] [7] Moreover, melatonin has been shown to directly signal to the SCN. The acute inhibitory effect of melatonin on neuronal activity seems to be mediated by melatonin receptor isoform 1 (MT1) receptor, 8 while the phase-resetting effect relies on melatonin receptor isoform 2 (MT2) receptor signalling. 9 The primary function of melatonin is to select information regarding the environmental light-dark cycle, especially in response to changes in day length, triggering endocrine changes. 2 The most relevant core clock genes are the Circadian Locomotor Output Cycles Kaput (CLOCK) gene, a transcription factor from the positive limb of the molecular clock, and brain and muscle ARNT-like 1 (BMAL1) gene. [5] [6] [7] Among the numerous target genes of CLOCK-BMAL1 are the cryptochrome (CRY) genes CRY1 and CRY2 and the period (PER) genes PER1-3.
5,10 CRY-PER heterodimers act as corepressors by binding to the CLOCK-BMAL1 complex and inhibit its interactions with various promoters and enhancers leading to switch-off CLOCK-BMAL1-induced gene transcription. 6, 7, 10 As a result, CRY and PER expression drops and the CLOCK-BMAL1 activity is restored 10 ( Figure 1 ). The first studies that were conducted on CLOCK mutant mice 11 produced a truncated CLOCK protein, capable of dimerizing with its partner BMAL1, but not binding to the regulatory E-box sequences in the promoters of PER1-2 and the CRY genes. 12 A secondary loop, including the repressor REV-ERBa and the enhancer retinoic acid-like orphan receptor a (RORa), provides stability of function by regulating BMAL1 expression. 13 The CLOCK mutant mice sustained circadian rhythmicity either in continuous darkness or in light-dark cycles, [13] [14] [15] indicating that CLOCK genes are not required for circadian rhythmicity. 13, 14 In contrast, BMAL1 knock-down mice experienced a complete loss of circadian rhythmicity in constant darkness. 16 PER1-mutant mice 17 presented only a slight alteration of circadian rhythmicity in constant darkness, whereas PER2-mutant mice were arrhythmic. 13, 18 The first studies to assess oscillations of a number of endocrine systems in humans enforced a state of arousal during the night, followed by sleep during the subsequent day. [19] [20] [21] These studies revealed that some (cortisol, thy- Both thyroid-releasing hormone (TRH) and TSH exhibit high-amplitude circadian oscillations in the blood with a peak between 2 and 4 am, whereas the amplitude of TSH oscillations is not influenced by sex, body mass index (BMI) or age. 22, 23 Triiodothyronine (T3) exhibits a peak with a phase delay of about 1.5 hours compared with the phase of TSH, while thyroxine (T4) exhibited weaker circadian amplitude. 22 Melatonin might further modulate the response of the anterior pituitary to TRH and of the thyroid to TSH. 24 Changes in TSH serum levels are smaller and those of freeT4 are greater at night, when melatonin levels are higher, so that the response of anterior pituitary to hypothalamic TRH and of thyroid to hypophyseal TSH may be influenced by the pineal hormone that may modulate the hypothalamic-pituitary-thyroid axis function and circadian rhythm. 24 In an animal model after hypophysectomy, the circadian clock genes PER1 and BMAL1 still displayed a 24-hour rhythmic expression in the rat thyroid gland. 25 Although the thyroid clock was not affected, thyroid hormonal oscillations were abolished and their levels were markedly lower compared to normal rats. 25 No daily oscillations of the TSH-receptor mRNA expression were found in control and/or hypophysectomized rats. 25 Thyroidectomized rats showed significantly altered daily pattern of PER2 expression in the stria terminalis and amygdala, without any effect on PER2 expression in the SCN, basolateral amygdala and the dentate gyrus. 26 It is likely that the tissue-specific effect of thyroid hormones on the regulation of PER2 expression implicates the involvement of additional mechanisms. 25 BMAL1 binding to the promoter region of the thyroid hormone-activating enzyme type 2 iodothyronine deiodinase (Dio2) regulated its expression in mice suggesting that circadian proteins can locally regulate the availability of thyroid hormones in a tissue-specific way. 27 Tissue-specific circadian expression of thyroid hormone receptors (TR) represents an additional level of regulation besides the HPA. In rodents, TRa was rhythmically expressed in the liver, where it was directly bound by BMAL1 28 and REV-ERBa/b. 29 Both TRa and TRb exhibited pronounced circadian oscillations in white and brown adipose tissue. 30 By contrast, the profile of TRa was constant over a 24-hour period in skeletal muscle and that of TRb in liver and skeletal muscle. 30 Although the circadian profile of TSH in humans is well documented, the underlying mechanism of such circadian regulation has not been explored. Cell-autonomous circadian clocks have been demonstrated in the primary human thyrocytes synchronized in vitro. 31 The expression levels of the BMAL1 were upregulated in tissue samples of follicular (FTC) and papillary thyroid carcinoma (PTC), as compared with normal thyroid tissue and benign nodules, whereas CRY2 was downregulated in both FTC and PTC. 31 Either increased or decreased T3 levels regulated the expression of BMAL1 and ROR in rat cardiomyocytes, while only decreased T3 levels altered PER2 expression in rat cardiomyocytes. 32 
| Clock genes and adrenal disorders
While pulsatile glucocorticoid (GC) release is controlled by a negative feedback loop involving glucocorticoid receptor (GR) signalling and ACTH suppression in the pituitary, 33, 34 circadian GC rhythm is regulated by 3 main factors: (i) the endocrine HPA axis, (ii) SCN-controlled autonomic innervation and (iii) local adrenocortical circadian clocks. 33, 35 The circadian rhythm of GC secretion and its reliance on the SCN persist despite constant environmental conditions and are abolished when the SCN is surgically removed. 36, 37 Adrenal glands are in the first line of peripheral organs that respond to light signals.
38
A 30-minutes light pulse stimulated adrenal PER1 expression followed by a corticosterone peak independently of ACTH. 38 Recent data in the rat foetal adrenal suggest that melatonin plays a role in the regulation of the clockcontrolled gene steroidogenic acute regulatory protein (StAR), a key protein involved in corticosterone synthesis,
The mammalian circadian clock feedback loop. During the day, BMAL and CLOCK form a heterodimer protein complex which binds to E-box in the promoter region of clock genes (Per, Cry, ROR and Rev-erb). Per protein synthesized in the cytoplasm translocates to the nucleus where heterodimerizes with Cry and inhibits CLOCK-BMAL transcriptional activity. During the dark phase, the Per-Cry repressor complex is degraded leading to activation of a new cycle of CLOCK-BMAL1 transcription. The second loop is composed of Rev-erb which is a product of CLOCK/BMAL transcriptional activity. During the day, Rev-erb suppresses BMAL gene expression through binding to Rev-erb /ROR response element (RRE). On the contrary, during the night, the BMAL expression is upregulated through binding of ROR to RRE as well as of BMAL1 and PER2 expression. 39 Maternal melatonin suppression of pregnant rat induced intrauterine growth retardation, affected the mRNA expression level of PER2, BMAL1, StAR, MT1 and early growth response protein 1 (Eg1) and was associated with reduced corticosterone levels. 40 Moreover, no increase in corticosterone was observed in foetal adrenals the mother of who was exposed all day to the light. 40 All these changes were reversed when the mother received a daily dose of melatonin. 40 ACTH induced a prompt increase in foetal adrenal corticosterone production and StAR, MC2R PER2 and BMAL1 gene expression. 40 In addition, PER2/CRY1 double mutant mice lacked circadian clock and exhibited defective hypothalamus/pituitary/adrenal axis regulation. 41 Clock genes expression was also investigated by RT-PCR in normal adrenal gland and adenomas. 42 It was
shown that human adrenal gland expressed the PER1, PER2, CRY2, CLOCK and BMAL1 clock genes. 42 Incubation with ACTH increased PER1 mRNA, BMAL1, StAR and 3b-hydroxysteroid-dehydrogenase (3b-HSD) protein levels, as well as cortisol and progesterone production, whereas melatonin inhibited these ACTH effects. 42 Similar direct inhibitory effects of melatonin over ACTH-stimulated cortisol production have been shown in the NCIH295R human adrenocortical carcinoma cell line. 43 These data suggest that in vivo the human adrenal gland contains a circadian clock-altering ACTH sensitivity during the course of the day. The role of the clock genes in adrenal medulla remains to be further clarified. In vitro, rat pheochromocytoma PC12 cells were found to exhibit oscillations of the clock genes BMAL1, PER1, REV-ERBa and CRY1 and to induce the circadian expression of a transcription factor involved in apoptosis and neural cell differentiation but not in catecholamine synthesis. 44 The role of clock genes, however, is well established in the dopamine synthesis and in CNS metabolism. Direct binding of CLOCK to dopamine-related genes regulated dopamine synthesis, release and transmission. Presynaptically, CLOCK inhibits the transcription of tyrosine hydroxylase and stimulated cholecystokinin which influences dopamine output and monoaminoxidase, the enzyme responsible for the breakdown of dopamine in the synaptic space. 45 
| Clock genes and pituitary disorders
The anterior pituitary is composed of five different cell lineages that show endocrine activities with patterns and rhythms. 46 These rhythms are mainly under the control of hypothalamic hormones. However, pituitary cells also contain their own molecular clock that is autonomously capable of oscillating. A significant correlation between the mRNA expression of POMC and PER2 has been revealed in serial cultures of corticotroph cells. 46 Knock-down of PER2 expression by siRNA in these cells resulted in a significant reduction in POMCmRNA level with or without CRH stimulation. 46 Conversely, treatment with BMP-4 and melatonin, both of which suppressed POMC expression, reduced PER2-mRNA as well as protein levels in these cells. In addition, lactosomatotroph cells exhibited an expressional correlation between prolactin and clock genes. SiRNA-mediated knock-down of CLOCK expression significantly reduced prolactin-mRNA levels in GH3 cells, whereas knock-down of BMAL1 expression did not change them. 46 Interestingly, in the same cells, CLOCKmRNA and protein levels did not fluctuate with melatonin, BMP-4 or forskolin, whereas BMAL1 expression was significantly increased by forskolin administration. 46 However, animal models, such as the BMAL1-R91A mutant rat, exhibited loss of the circadian pattern of endogenous clock-controlled genes and prolactin-gene suggesting the presence of a local oscillator in the pituitary. 47 It was further revealed that prolactin pulse activity depends on a specific promoter-binding region of E-box. 48 In particular, the E-box133 site binds a specific array of circadian components, such as BMAL1, CRY1 and PER 1-3, in which circadian inputs are critical for prolactin pulse activity. 49 In human autopsied pituitaries, PER1-mRNA expression showed daytime-dependent differences according to time of death, whereas the protein levels of PER1, CRY1 and CLOCK did not fluctuate with time of day. 47, 50 
| Clock genes and fertility
In vitro studies have shown a clear bidirectional association between clock gene expression and sexual hormone regulation. Oestradiol is synthesized in response to follicular stimulating hormone (FSH) and luteinizing hormone (LH) stimulation to the ovary. FSH and LH induced PER1 and PER2 expression in ovariectomized rat granulosa cells. 51 Ovarian follicular cells displayed a phasic sensitivity to gonadotropins, suggesting the presence of a circadian oscillator in granulose and theca cells. 52 Moreover, ovarian steroid feedback affected the timing of clock gene expression in several tissues, including the uterus, pituitary and ovary. Ovarian follicular cells also express melatonin receptors indirectly modulating the timing of the ovarian clock. According to recent data, the timing of ovulation depends not only on the SCN-dependent rhythm of LH secretion, but also on the timing of ovarian sensitivity to gonadotropins set by the ovarian clock. 53 Rat ovaries expressed rhythmically BMAL1 with highest mRNA levels around the time of light onset 54 ; in contrast, PER2-mRNA levels were higher at the time of light withdrawal. 54 BMAL1 was also expressed in mouse Leydig cells and was linked to circadian oscillations. 55 BMAL1 knockdown mice showed disrupted expression of progesterone production, 56 whereas CLOCK gene altered oestradiol signalling. 57 Oestradiol downregulated PER2 expression in the uterus but not in the SCN of mice and altered the circadian rhythmicity of PER1 and PER2. 58 The different regulation of clock genes by oestradiol in central and peripheral tissues is probably attributed to the differential expression of oestrogen receptors (ERs). Androgens also exhibit direct and tissue-specific effects on clock gene expression. 59 Both male and female mice knock-down for BMAL1 have been shown to suffer from infertility; 60 BMAL1 knock-down male mice, in particular, were deficient in the production of testosterone. 60 BMAL1 knock-down females mice exhibited delayed puberty, irregular oestrous cycles, and smaller ovaries and uterus although there were able to ovulate. 60, 61 The absence of BMAL1 resulted in loss of circadian rhythms, acceleration of ageing, shortened lifespan and reduced fertility in standard BMAL1 knockout mice 62 ; mutant mice for PER1
and PER2 were fertile as young adults. 17, 18 In addition, more than 80% of the PER1 and PER2 mutants became pregnant, but successful parturition and the numbers of pups weaned were reduced compared to wild-type mice. 63 It was suggested that disruption of these genes could accelerate reproductive ageing. 63 In vitro studies in rats have shown that melatonin treatment reduced the increased response of LH to GnRH in acyclic rats and produced a pituitary responsiveness similar to that of young cyclic rats. After melatonin treatment, LH and FSH concentrations decreased to amounts similar to those observed in young cyclic rats; however, plasma concentrations of oestradiol and progesterone were not reduced 63, 64 Hyperandrogenemia, which is a common feature of the polycystic ovary syndrome (PCOS), has been found to change the timing of clock gene expression in the liver and ovarian follicle in rats; both tissues associated with metabolic and reproductive function, respectively. 65 Clock genes were expressed also in GnRH neurons, whereas GnRH neuron activation through kisspeptin was also regulated rhythmically following a circadian basis. 66 Abnormalities in kisspeptin gene (KISS) and its receptor (GPR54) have been reported in PCOS women and could be a target of endocrine and metabolic cues of this syndrome. 67 The circadian timing system that is evident in animals also operates in humans. Recently, the reproductive capacity of women possessing polymorphisms in BMAL1, BMAL2, CLOCK and NPAS2 genes has been studied. 68 Interestingly, a single nucleotide peptide (SNP) in the BMAL1 gene (rs2278749 TT) was associated with increased number of pregnancies, although the number of miscarriages was also greatly increased, while NPAS2 rs11673746 T carriers had fewer miscarriages. 68 An association between shift work and prolonged waiting time to pregnancy has been reported, 69 whereas it has also been suggested that the sleep and inherent circadian rhythm disturbances of shift work could lead to menstrual irregularities. 70 A number of internal and external factors including light perception also strongly influence the onset of puberty. 71 Puberty initiates in the brain and requires the activation of cellular mechanisms that control and regulate different levels of the brain-pituitary-gonadal axis. An increase in hypothalamic KISS stimulates the production of GnRH and pituitary gonadotropins which stimulate gonadal maturation and steroid production. Continuous light delays gametogenesis progression and inhibits the onset of puberty. Animals exposed to different photoperiods present significant expression differences in clock and reproductive axis-related genes well before the first detectable endocrine and morphological responses of the brain-pituitary-gonadal axis. 72 
| CLOCK GENES AND METABOLIC DYSFUNCTION
Changes similar to shift workers in the diurnal expression of CLOCK during Ramadan have been reported. CLOCK gene expression was significantly higher in morning than in evening, whereas no significant difference was noted between morning and evening adiponectin levels. 73 It has been also shown that clock gene expression in human subcutaneous adipose tissue (SAT) is regulated by body weight changes (the expression of PER2 was increased after the weight loss) and associated with body mass index (BMI), serum cholesterol levels and the expression of metabolic and inflammatory genes. 74 Expression of clock genes in monocytes was also tightly correlated with levels of blood lipids and with expression of metabolic and inflammatory genes. Thus, modulation of the dietary fat and carbohydrate content could alter the function of the central and peripheral circadian clocks in humans. 75 
| Type 2 diabetes mellitus
Pancreatic islets secrete insulin to maintain glucose homoeostasis. Insulin secretion displays a diurnal rhythm in humans, peaking at roughly 05:00 PM with a nadir at 04:00 AM. 76 This rhythmic control of insulin release is dysregulated in humans with diabetes mellitus, and the circadian clock affects this process.
77-83
Pancreatic islets possess self-sustained circadian gene and protein oscillations of the transcription factors CLOCK and BMAL1.
74-76 BMAL1 gene regulates many b-cell genes and affects insulin secretion and glucose tolerance.
83-87 BMAL1
and CLOCK knockout mice exhibited abnormal glucose tolerance, approximately 50% reduction in insulin secretion and 23% decrease in islet proliferation compared to wild type. These alterations mimic those seen in human diabetic islets; it appears that BMAL1 gene expression plays an important role in the impaired islet function of human T2DM. 78, 79 Additionally, disruption of the negative regulators of the clock system, PERs and CRYs, was associated with hyperinsulinemia. 87 Gluconeogenesis was also abolished by deletion of BMAL1 and suppressed in CLOCK mutants, but the counter-regulatory response of corticosterone and glucagon to insulininduced hypoglycaemia was retained. 88 It is well documented that melatonin influences insulin secretion mediated by G protein-coupled melatonin receptor isoforms, MT1 and MT2, present in rat and human pancreatic islets. 87, 89 Polymorphisms in MTNR1B increase the risk for T2DM, 87 whereas recent investigations showed decreased melatonin plasma levels in T2DM rats. 89 In clinical studies, melatonin has shown to reduce fasting plasma glucose and serum insulin concentrations as well as total HDL cholesterol ratio and systolic and diastolic blood pressure. Melatonin treatment also significantly increased quantitative insulin sensitivity and serum HDL cholesterol. 90 Gluconeogenesis was also abolished by deletion of BMAL1 and suppressed in CLOCK mutants, but the counter-regulatory response of corticosterone and glucagon to insulininduced hypoglycaemia was retained. 91 In humans, the prevalence of T2DM has been increasing worldwide. 5, 92 It is well recognized that several genetic, as well as lifestyle, factors are associated with the development of T2DM. [92] [93] [94] Insulin sensitivity is reduced in shift workers, accompanied by increased b-cell activity, suggesting the development of a prediabetic state. 95 Studies in human have found that various SNPs exhibit significant associations with T2DM 96 although the underlying mechanisms have not been fully elucidated. In particular, CLOCK SNPs have been associated with obesity, 97 hyperglycaemia and a higher prevalence of T2DM in cross-sectional studies. 76, 77, 98 A gene-diet interaction has been also found between the CLOCK-rs4580704 (C > G) SNP and monounsaturated (MUFA) intake and insulin resistance. 6, 99 A significant association between the CLOCK-rs4580704 SNP and T2DM incidence has been observed in 3671 non-T2DM participants, with variant allele (G) carriers showing decreased incidence compared with CC homozygotes. This protection was more significant in the group with high MUFA diet. 6 An AC haplotype of BMAL1-rs7950226-rs11022775 showed a significant association with T2DM in 1304 individuals from 424 British families. 83 A recent report indicated a significant association between the combination of NOC (CCR4 carbon catabolite repression 4-like gene, CCRN4L) rs9684900 and BMAL1-rs2290035 with fasting blood glucose levels among 1510 nondiabetic Chinese subjects. 100 In a further European study, the minor allele T of BMAL1-rs11022775 was associated with a higher odds ratio of T2DM than allele C in Asian populations, but the opposite association was observed in white European cohorts. 101 In 346 pregnant Greek women, the frequency of the C allele of BMAL1-rs11022775 gene was significantly higher in patients with gestational diabetes mellitus than in controls. 102 BMAL1-rs11022775, rs2290035 and BMAL2-rs7958822 showed no significantly increased or decreased risk for T2DM in either sex. 5 
BMAL2-rs7958822
A/G and A/A genotypes were associated with a higher prevalence of T2DM than the G/G genotype among obese individuals in Japan. 5 Regarding other circadian rhythm-related genes, 121 SNPs tagging ARNTL, ARNTL2, CLOCK, CRY1, CRY2, PER1, PER2, PER3 and TIMELESS were assessed in a study population of 1.715 nondiabetic German individuals; four CRY2 SNPs were associated with fasting glycaemia. 10 Carriers of these SNPs minor alleles revealed elevated fasting glycaemia and reduced liver fat content. In human liver tissue samples, CRY2-mRNA expression was directly associated with hepatic triglyceride content suggesting that CRY2 promotes triglyceride storage and concomitantly limits glucose production. The antisteatotic effects of the glucose-raising CRY2 alleles may explain why these alleles do not increase T2DM risk. 10 
| Type 1 diabetes mellitus (T1DM)
Involvement of clock genes in autoimmunity is also well known. Recent studies showed that Th17 differentiation is partly controlled by the circadian clock.
103 BMAL1 regulates also diurnal oscillations of Ly6C (hi) inflammatory monocytes 104 and CRY the expression of pro-inflammatory cytokines. 105 In particular, ARNTL2 gene has been discovered as a candidate gene for T1DM within the Idd6 locus of the nonobese diabetic mouse, 106, 107 regulating proliferation of peripheral CD4 (+) T cells and thus diabetes development. 108, 109 ARNTL2 binds to the promoter of the interleukin-21 (IL-21) gene, which itself controls the proliferation of immune cells and associated with human T1DM. 110 Although studies have shown that there is no difference in the distribution of SNPs between patients with T1DM and controls, suggesting that IL21 exerts little effect in the susceptibility for T1DM, 110 recent findings showed that IL-21-producing cells are increased in T1DM. 111 Increased expression of PER1 and BMAL1 genes combined with elevated melatonin has also been described in a rat model of T1DM induced by streptozotocin.
112,113
| Clock genes and melatonin
Circulating melatonin is produced in the pineal gland, under tight control by the central circadian pacemaker in the SCN. 1,2 Melatonin production is characteristically low in the presence of light and increases during the night. 112, 113 The SCN-activated, light-inhibited production of melatonin conveys the message of darkness to the clock and induces night-state physiological functions, such as sleep/wake cycle, blood pressure alterations and metabolism. Clinically, meaningful effects of melatonin treatment have been demonstrated in circadian rhythm-related sleep disorders, jet lag and shift work, insomnia in children with neurodevelopmental disorders, poor (nonrestorative) sleep quality, nondipping nocturnal blood pressure (nocturnal hypertension) and Alzheimer's disease (AD). 4 Melatonin influences also insulin secretion, as well as glucagon and somatostatin secretion, both in vivo and in vitro.
Interactions between melatonin and insulin have been well described in vitro in diabetic rat models. 112, 113 Both type 2 diabetic rats and T2DM patients exhibited decreased melatonin levels and slightly increased insulin levels, whereas type 1 diabetic rats showed extremely reduced levels or absence of insulin, but statistically significant increased melatonin levels. Melatonin levels in blood plasma, as well as the activity of the key enzyme of melatonin synthesis in the pineal, were also found to be lower in type 2 diabetic rats compared to controls. In contrast, melatonin mRNA levels were increased although insulin receptor mRNA levels were decreased in type 1 diabetic rats, confirming the presence of a close relationship between insulin and melatonin. 9 In vitro, melatonin application to cultured SCN explants affected the amplitude and the phase of the circadian rhythm of neuronal firing. 9 The acute inhibitory effect of melatonin on neuronal activity seems to be mediated by MT1 receptor, while the phase-resetting effect relies on MT2 receptor signalling. 114 Polymorphisms in melatonin receptors have been associated with diabetes risk. 87 In humans and monkeys, acute melatonin administration suppressed the production of cortisol, 39 whereas timed melatonin application in foetal rats entrained adrenal gland rhythms. 115 It is well known that misalignment of melatonin and cortisol rhythms occurred during shift work. [116] [117] [118] Shift workers develop several metabolic disorders including hypertriglyceridemia, reduced insulin sensitivity and postprandial ghrelin release during the night shift work.
116-118

| Clock genes and adiponectin
Adiponectin is one of several adipokines that exhibits a time-of-day-dependent rhythm in humans, peaking in the circulation between 12:00 and 02:00 PM.
3,119 Its secretion shows both ultradian and circadian rhythms, with a nadir in the early morning hours in healthy adults. 120, 121 Adiponectin is best known as an insulin sensitizer, with circulating levels that vary inversely with body mass index (BMI). 1 Furthermore, hypoadiponectinemic mice exhibited a shorter activity period under constant conditions and dampened circadian locomotor rhythms with increased light-phase activity compared to controls. Clock gene rhythms were phaseadvanced in the liver and skeletal muscle. The introduction of the human adiponectin transgene into the liver of these mice restored locomotor rhythmicity. 121 
| Clock genes and leptin
Circulating leptin shows a diurnal rhythm, peaking at night in humans. Leptin is secreted from white adipose tissue and signals via appetite centres in the hypothalamus to promote satiety and prevent excess energy consumption. 1, 119 Despite having no direct effect on locomotor activity, leptin induced PER expression in the SCN and potentiated the phase-shifting effects of light in female mice. 122 
| Clock genes and ghrelin
Ghrelin is secreted from gastric oxyntic gland cells in anticipation of feeding, regardless of the light-dark cycle. 123, 124 Ghrelin stimulates appetite via its actions on the hypothalamic orexigenic peptides, neuropeptide Y and orexin, and on mesolimbic reward centres. 125 In shift workers, the postprandial ghrelin slump was attenuated, leading to overeating. 126 Ghrelin could feed back to the circadian clock by directly affecting clock gene expression in the SCN. 126 
| CLOCK GENES AND CANCER
Lately, circadian disruption has been recognized as a potential independent risk factor for cancer development. 127 In vivo and in vitro studies have demonstrated that disruption of circadian rhythms is linked to tumour progression and mammalian tumorigenesis for several malignancies such as liver cancer, 128 oral squamous cell carcinoma, 129 gastric, pancreatic and colorectal carcinoma. 130 Clock genes contribute to the occurrence and development of tumours by regulating and interfering with oncogenes (c-myc), tumoursuppressor genes (P53 and P21), genes involved in the regulation of the cell cycle and vascular endothelial growth factor. These target genes regulated by the biological clock genes are involved in DNA damage repair, cell proliferation and apoptosis. 131 The detection of clock genes' expression in endocrine malignancies such as the FTC and PTC as well as in adrenocortical carcinoma 31, 43 in vivo and in vitro could lead to the development of therapeutic molecular targets altering the expression of these genes.
| CLOCK GENES AND THERAPEUTIC TARGETS
Several molecules targeting molecular intrinsic clock have been used in vitro. 132 Recently, a small molecule, longdaysin, has been shown to prolong the circadian period by targeting multiple kinases simultaneously (CKId, CKIa and ERK2), leading to PER1 degradation. 133 Stabilization of CRY proteins (through prevention of ubiquitination and degradation) by another small molecule (KL001) is an attractive therapeutic prospect for diabetes as it has been shown to suppress hepatic glucagon-induced glucose production. 134 Additionally, other molecules targeting other clock components, such as REV-ERBa agonists, seem to enhance PER2, suppress CRY2 and shift BMAL1. One particular molecule (SR9009) can also inhibit the accumulation of fat and development of dyslipidaemia and hyperglycaemia in obesity models. 135 
| CONCLUSION
Clock genes have a distinct role in circadian regulation of different endocrine signals shown largely in vitro, whereas data in humans are relatively scarce. In addition, melatonin seems to influence clock gene expression and in some cases being involved in endocrine disorders such as cortisol and insulin secretion. Pancreatic islets possess self-sustained circadian gene and protein oscillations of the transcription factors CLOCK and BMAL1. BMAL1 plays an important role in impaired islet function in human T2DM, while ARNTL2 is considered as a candidate gene for the development of T1DM as PER1 and BMAL1 clock genes seem to be over-expressed. PER1 and BMAL1 also display a 24-hour rhythmic expression in the thyroid gland. BMAL1 is upregulated in tissue samples of FTC and PTC compared to normal thyroid and benign nodules, whereas CRY2 is downregulated. Core clock genes interfere with oestradiol signalling, and inversely, oestradiol alters the rhythms of PER1 and PER2 gene expression in peripheral tissues. The human adrenal gland and adrenal adenoma express PER1, PER2, CRY2, CLOCK and BMAL1 clock genes. Pituitary cells also contain their own molecular clock that is autonomously capable of oscillating. A significant correlation between the expression of POMC and PER 2 and between prolactin and CLOCK has been also found in corticotroph and lactosomatotroph cells. Clock genes in endocrine cell regulation show a tissue-specific expression representing an additional level of regulation. A number of endocrine malignant neoplasms exhibit alterations of clock gene expression. Molecules that could modify the abnormal expression of clock genes in a number of disorders could present a novel and attractive new therapeutic option.
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